THE
ALL4CURE
STORY.
OUR MISSION.
At All4Cure, we are on a mission to transform cancer treatment and research by leveraging a transparent, collaborative ecosystem that harnesses the power of collective learning to improve outcomes for patients with multiple myeloma – and eventually all cancers.
​
We are forging new paths and redefining the standard of care – bringing oncologists, researchers, and patients together to drive smarter, data-informed treatment decisions and accelerate progress toward cures.
All4Cure started with a deeply personal vision from Dr. Carl Anthony Blau, a dedicated hematologist and researcher who saw firsthand how isolated and fragmented cancer care can be—especially as a multiple myeloma patient himself. He envisioned a better way: one where patients, doctors, and researchers could come together to share knowledge, not just in theory, but in real-time, around real people.
That idea became All4Cure—a collaborative oncology ecosystem with a platform where patients contribute their medical histories, clinicians add insight and guidance, and researchers learn from each case to uncover broader patterns. It's a living, evolving community that supports each patient while also building a powerful, de-identified dataset to fuel discovery and innovation in oncology.
OUR STORY.
WHO WE ARE.
Meet our Founder.
C. Anthony “Tony” Blau, MD
Dr. Tony Blau dedicated 27 years as a Professor of Medicine/Hematology and physician-scientist at the University of Washington, where his research spanned hematopoiesis, gene therapy, stem cell biology, genomics, and cancer.
During his tenure, he co-founded the Institute for Stem Cell and Regenerative Medicine and founded the Center for Cancer Innovation, a pioneering initiative that united a distributed network of investigators to support patients with advanced cancer. Throughout his career, his driving focus has been translating the latest scientific breakthroughs into real-world treatments for patients facing otherwise incurable diseases.
One profound realization emerged from his work: a critical gap in cancer care. Patients were often disconnected from the cutting-edge advancements that could change—or even save—their lives. This insight, combined with his own myeloma diagnosis in 2015, ignited a deep determination to close this gap and create a seamless bridge between patients, clinicians, and researchers.
Our Core Leadership.
The All4Cure leadership team brings together decades of unmatched experience across cancer care, health technology, clinical trials and data, and cutting-edge drug development.
Our Team.
The All4Cure team is powered by dedicated clinicians, engineers, data specialists, and operations experts who combine deep medical and technical experience, meticulous attention to detail, and a shared passion for advancing patient care.
OUR VALUES.
"All4Cure is indivisibly bound to the best interests of the patients who entrust their information to us."
Advocacy
We help patients whenever and in whatever ways we can.
​
We provide input whenever it may be helpful for our patients.
Transparency
We disclose all actual and perceived conflicts of interest.
​
We disclose any commercial relationship that may be regarded as a conflict of interest.
Equality
We give all patients enrolled in All4Cure equal access to the benefits of participation.
​
We give every All4Cure patient equal access to other All4Cure patients.
Respect
We treat all who treat our patients with respect.
​
We invite a diversity of opinions to find the best answers for our patients.
All4Cure is founded on these four guiding pillars.
Today, All4Cure stands as a testament to the power of shared knowledge and collaborative care. We're not just a platform; we're a community dedicated to transforming every cancer patient's experience into optimized care.
OUR ADVISORS.
Kenneth Anderson, MD
Kraft Family Professor of Medicine, Harvard Medical School
Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute
Director, LeBow Institute for Myeloma Therapeutics
​
Doris Duke Distinguished Clinical Research Scientist
Brian Decker, MBA
President & CEO at EMOL Health
​
Collaborator with community healthcare providers, researchers, and biopharma companies to support oncology patient journeys
Mimi Choon-Quinones,
Ph.D, LLM, MBA, MA
Senior Vice President, Blood Cancer Research Scientist (MRD, Policy, Advocacy, Access & HTA), International Myeloma Foundation
Founder & Pro-Bono Board Chairwoman (Accelerate Access To Medicines, Screening & Clinical Trials), Partners For Patients NGO
Kevin Sidow
Former President & CEO, Moximed Inc.
Former President & CEO, St. Francis Medical Technologies Inc.
​
Former Worldwide President, DePuy Inc. (overseeing Johnson & Johnson’s global orthopedic, spine, trauma and sports medicine businesses)
Board of Directors, Meals on Wheels of SF
​
Melissa Waggener Zorkin
Global CEO and Founder, We. Communications
​
Inductee of the PRWeek Hall of Fame
​
ICCO Hall of Fame
​
PRWeek Power List Honoree
Aaron Germain
Advisor, All4Cure
William Bensinger, MD
Myeloma Specialist
​
Former Director of Autologous Stem Cell Transplant Program, Fred Hutchinson Cancer Research Center
​
Former Professor of Medicine, University of Washington
​
2015 Newsweek Top Cancer Doctor in Multiple Myeloma and Stem Cell Transplantation
Brian G.M. Durie, MD
Hematologist/Oncologist, Cedars-Sinai Outpatient Cancer Center
Co-Founder, International Myeloma Foundation
​
Co-Chair, Myeloma Committee Southwest Oncology Group (SWOG)
​
Director of Myeloma Research, AMyC Clinical Trials Consortium
​
Hon MD University of Brussels